Avai Bio and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
LAS VEGAS, Sept. 18, 2025 /PRNewswire/ -- Avai Bio Inc. (OTCQB: AVAI) ("Avai Bio" or the "Company"), a Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based biotechnology leader, today announced the formation of a Joint Venture and License Agreement to establish Klothonova, Inc., a new Nevada corporation focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells.
Under the terms of the agreement, Klothonova will leverage Austrianova's proprietary cellencapsulation technology to develop and commercialize treatments targeting Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion. Austrianova, renowned for its expertise in cell biology, GMP-grade cell products, and encapsulation technologies - backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies - will contribute its intellectual property and 'know-how' to the venture. Avai Bio will provide capital, along with additional resources, to support Klothonova's formation and operations.
Klothonova will operate as a 50/50 joint venture, with ownership equally split between Avai Bio and Austrianova. The company will be focusing on developing innovative treatments through the over expression of the Klotho protein, encapsulated using Austrianova's cutting-edge technology. This exclusive license will enable Klothonova to address critical medical needs and explore longevity-enhancing solutions across global markets.
"We are thrilled to partner with Austrianova, whose world-class expertise in cell encapsulation and GMP manufacturing complements our vision for advancing transformative healthcare solutions," said Chris Winter, Chief Executive Officer (CEO) at Avai Bio.
"Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time."
Austrianova's CEO, Brian Salmons, added, "This joint venture with Avai Bio allows us to combine our proprietary technologies with Avai Bio's resources to accelerate the development of Klotho-based therapies. We are excited about the potential to improve patient outcomes and promote healthier, longer lives."
Klotho is regarded as an 'anti-aging' protein, known for its crucial role in modulating aging and supporting diverse physiological functions. Discovered in 1997, it is primarily produced in the kidneys and brain and has been linked to improved cognitive function, cardiovascular health, and kidney function, while also showing potential in combating age-related diseases such as Alzheimer's, cancer, and heart disease. By leveraging Klotho's therapeutic properties through advanced cell encapsulation technology, Klothonova is poised to become a leader in the biotech industry, with a mission to develop and commercialize innovative treatments that enhance quality of life and promote longevity
Klothonova will prioritize the development of treatments for major indications, with each program independently managed to ensure focused progress. This strategic collaboration positions Klothonova to lead in the rapidly evolving field of cell-based therapeutics.
About Avai Bio Inc.
Avai Bio Inc. is an emerging Nevada-based technology company dedicated to advancing innovative technologies and strategic partnerships to drive value in the biotech and technology sectors.
About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peerreviewed publications and partnerships with global pharmaceutical and biotech companies.
More information about Avai Bio can be found at https://avaibio.com
You can also follow us on social media at:
https://twitter.com/Avai BioTechAI
https://www.facebook.com/Avai BioTechAI
https://www.youtube.com/@Avai BioTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (https://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avai Bio Inc.
info@avaibio.com
Logo: https://mma.prnewswire.com/media/2370694/5517509/Avai Bio_Technologies.jpg
